Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: Journal – The Jakarta Post – Jakarta Post
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 tria…
-
General13 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News21 hours agoStudents say new facility would be better in rural areas of Queensland
-
General15 hours ago‘We are here for you’: PM to bring help to flood zones
-
General10 hours agoStephanie Scott’s murder caused a ‘seismic’ shock in Leeton, and the hurt remains